⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

POLYMED - IntraDay Trade Analysis with Live Signals

← Back to List

⭐ Rating: 2.3

Last Updated Time : 19 Sept 26, 12:18 pm

Key Parameters

⭐ IntraDay Trade Rating: 2.3

RSI49.6
MACD-2.83
Volume1,55,636
Avg Vol 1Wk1,05,743
Low price1,182 ₹
High price2,094 ₹
Current Price1,735 ₹
DMA 501,707 ₹
Show all parameters (20 more)
Stock CodePOLYMED
Market Cap17,591 Cr.
High / Low2,094 ₹
Stock P/E51.6
Book Value301 ₹
Dividend Yield0.20 %
ROCE13.4 %
ROE9.62 %
Face Value5.00 ₹
DMA 2001,677 ₹
Chg in FII Hold-0.36 %
Chg in DII Hold0.48 %
PAT Qtr88.1 Cr.
PAT Prev Qtr80.6 Cr.
PEG Ratio2.94
Debt to equity0.08
52w Index60.6 %
Qtr Profit Var0.22 %
EPS33.2 ₹
Industry PE33.1

🧾 Trade Setup

Buy at 1,725 ₹ with a stop-loss order at 1,690 ₹ – this leverages the strong volume and momentum while incorporating a necessary risk buffer. A further exit level would be 1,745 ₹ to capture additional upside potential if the price continues to move upwards. Overall, proceed with caution given the premium valuation and recent profit decline.

✅ Positive

Strong daily volume of 155k units indicates decent interest today. The recent EPS growth of 0.22% quarter-over-quarter suggests continued operational improvement, which could fuel short-term momentum. Furthermore, the DII holding increased by 0.48%, implying some institutional confidence.

⚠️ Limitation

The high P/E ratio of 51.6 relative to the industry PE of 33.1 indicates a premium valuation; this stock is potentially overvalued and susceptible to significant corrections if growth expectations aren't met, particularly given the recent profit decline. The negative MACD (-2.83) suggests weak momentum and bearish signals.

📉 Company Negative News

Recent news highlights declining net profits despite rising revenue, raising concerns about profitability sustainability and potential headwinds impacting investor sentiment today.

📈 Company Positive News

The company announced a 12.3% rise in FY26 revenue, suggesting continued growth prospects and potentially attracting buyers looking for expansion opportunities.

🏭 Industry

The pharmaceutical sector is generally resilient but sensitive to regulatory changes and patent expirations. Given the industry's average PE of 33.1, POLYMED’s current valuation appears elevated, reflecting broader market sentiment towards healthcare stocks.

Choose Technical Analysis or Fundamental Analysis above to load it.

How POLYMED Rates Across All Strategies

★ 2.2
Enter at 1,707 ₹ – this represents a slight dip from the immediate hi…
Intraday
★ 2.3
You're viewing this analysis below.
★ 2.3
An ideal entry price zone would be between 1,600 ₹ and 1,700 ₹, capit…
★ 2.7
Entry Zone: 1,700 - 1,725 ₹ (based on support levels near the 50 DMA).
★ 2.8
Given the current valuation, an entry point at 1,600 ₹ would represen…

NIFTY 50 · Intraday Trading

NEXT 50 · Intraday Trading

MIDCAP · Intraday Trading

SMALLCAP · Intraday Trading